TY - JOUR
T1 - Multimodal prehabilitation to improve the clinical outcomes of frail elderly patients with gastric cancer
T2 - a study protocol for a multicentre randomised controlled trial (GISSG + 2201)
AU - Sun, Yuqi
AU - Tian, Yulong
AU - Cao, Shougen
AU - Li, Leping
AU - Yu, Wenbin
AU - Ding, Yinlu
AU - Wang, Xixun
AU - Kong, Ying
AU - Wang, Xinjian
AU - Wang, Hao
AU - Hui, Xizeng
AU - Qu, Jianjun
AU - Wang, Hong Bo
AU - Duan, Quanhong
AU - Yang, Daogui
AU - Zhang, Huanhu
AU - Zhou, Shaofei
AU - Liu, Xiaodong
AU - Li, Zequn
AU - Meng, Cheng
AU - Kehlet, Henrik
AU - Zhou, Yanbing
N1 - Funding Information:
The present trial is supported by Major Scientific and Technological Innovation Projects in Shandong Province (2019JZZ010104). The funder is not involved in the aspects of trial design, date collection and analysis, and manuscript writing.
Publisher Copyright:
© 2023 BMJ Open. All rights reserved.
PY - 2023
Y1 - 2023
N2 - Introduction Gastric cancer (GC) diagnosed in the elderly population has become a serious public health problem worldwide. Given the combined effects of frailty and the consequences of cancer treatment, older individuals with GC are more likely than young patients to suffer from postoperative complications and poor clinical outcomes. Nutrition, functional capacity and psychological state-based multimodal prehabilitation, which is dominated by Enhanced Recovery After Surgery (ERAS) pathway management, has been shown to reduce postoperative complications, promote functional recovery and decrease hospitalisation time in certain malignancies. However, no previous studies have investigated the clinical application of multimodal prehabilitation in frail older patients with GC. Methods and analysis The study is a prospective, multicentre randomised controlled trial in which a total of 368 participants who meet the inclusion criteria will be randomised into either a prehabilitation group or an ERAS group. The prehabilitation group will receive multimodal prehabilitation combined with ERAS at least 2 weeks before the gastrectomy is performed, including physical and respiratory training, nutritional support, and therapy and psychosocial treatment. The ERAS group patients will be treated according to the ERAS pathway. All interventions will be supervised by family members. The primary outcome measures are the incidence and severity of postoperative complications. Secondary outcomes include survival, functional capacity and other short-term postoperative outcomes. Overall, the multimodal prehabilitation protocol may improve functional capacity, reduce the surgical stress response and concomitant systemic inflammation, and potentially modulate the tumour microenvironment to improve short-term and long-term clinical outcomes and patients' quality of life. Ethics and dissemination All procedures and participating centres of this study were approved by their respective ethics committees (QYFYKYLL 916111920). The final study results will be published separately in peer-reviewed journals. Trial registration number NCT05352802.
AB - Introduction Gastric cancer (GC) diagnosed in the elderly population has become a serious public health problem worldwide. Given the combined effects of frailty and the consequences of cancer treatment, older individuals with GC are more likely than young patients to suffer from postoperative complications and poor clinical outcomes. Nutrition, functional capacity and psychological state-based multimodal prehabilitation, which is dominated by Enhanced Recovery After Surgery (ERAS) pathway management, has been shown to reduce postoperative complications, promote functional recovery and decrease hospitalisation time in certain malignancies. However, no previous studies have investigated the clinical application of multimodal prehabilitation in frail older patients with GC. Methods and analysis The study is a prospective, multicentre randomised controlled trial in which a total of 368 participants who meet the inclusion criteria will be randomised into either a prehabilitation group or an ERAS group. The prehabilitation group will receive multimodal prehabilitation combined with ERAS at least 2 weeks before the gastrectomy is performed, including physical and respiratory training, nutritional support, and therapy and psychosocial treatment. The ERAS group patients will be treated according to the ERAS pathway. All interventions will be supervised by family members. The primary outcome measures are the incidence and severity of postoperative complications. Secondary outcomes include survival, functional capacity and other short-term postoperative outcomes. Overall, the multimodal prehabilitation protocol may improve functional capacity, reduce the surgical stress response and concomitant systemic inflammation, and potentially modulate the tumour microenvironment to improve short-term and long-term clinical outcomes and patients' quality of life. Ethics and dissemination All procedures and participating centres of this study were approved by their respective ethics committees (QYFYKYLL 916111920). The final study results will be published separately in peer-reviewed journals. Trial registration number NCT05352802.
KW - Gastrointestinal tumours
KW - Protocols & guidelines
KW - Rehabilitation medicine
U2 - 10.1136/bmjopen-2023-071714
DO - 10.1136/bmjopen-2023-071714
M3 - Journal article
C2 - 37816552
AN - SCOPUS:85175419657
SN - 2044-6055
VL - 13
JO - BMJ Open
JF - BMJ Open
IS - 10
M1 - e071714
ER -